BILIARY TRACT ADENOCARCINOMA
Clinical trials for BILIARY TRACT ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BILIARY TRACT ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BILIARY TRACT ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bile duct cancer: targeted therapy duo takes on standard chemo
Disease control Recruiting nowThis study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…
Matched conditions: BILIARY TRACT ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control Recruiting nowThis study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrin…
Matched conditions: BILIARY TRACT ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to make inoperable bile duct cancer removable
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy can shrink advanced bile duct tumors enough for surgery. About 20 adults with locally advanced, inoperable bile duct cancer will receive the combination treatment. The main goal is to see h…
Matched conditions: BILIARY TRACT ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New targeted drug shows promise for hard-to-treat stomach and pancreatic cancers
Disease control Recruiting nowThis study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…
Matched conditions: BILIARY TRACT ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC